Therapy of B-cell malignancies by anti–HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways

A humanized IgG4 anti–HLA-DR monoclonal antibody (IMMU-114), engineered to avoid side effects associated with complement activation, was examined for binding and cytotoxicity on leukemia, lymphoma, and multiple myeloma cell lines and chronic lymphocytic leukemia (CLL) patient specimens, followed by...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Stein, Rhona, Gupta, Pankaj, Chen, Xiaochuan, Cardillo, Thomas M., Furman, Richard R., Chen, Susan, Chang, Chien-Hsing, Goldenberg, David M.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2010
Témata:
Lymphoid Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2892948/
https://ncbi.nlm.nih.gov/pubmed/20101022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-06-228288
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky